Cargando…
Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test
PURPOSE: To assess changes in the central and peripheral contrast sensitivity in severe primary open-angle glaucoma (POAG) patients using a computer-based Spaeth/Richman contrast sensitivity test (SPARCS) over a period of 24 months. METHODS: Our pilot, observational study included 15 patients (30 ey...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780179/ https://www.ncbi.nlm.nih.gov/pubmed/33447729 http://dx.doi.org/10.1177/2515841420977412 |
_version_ | 1783631463109885952 |
---|---|
author | Ichhpujani, Parul Singh, Tanu Thakur, Sahil Singh, Rohan Bir Kumar, Suresh |
author_facet | Ichhpujani, Parul Singh, Tanu Thakur, Sahil Singh, Rohan Bir Kumar, Suresh |
author_sort | Ichhpujani, Parul |
collection | PubMed |
description | PURPOSE: To assess changes in the central and peripheral contrast sensitivity in severe primary open-angle glaucoma (POAG) patients using a computer-based Spaeth/Richman contrast sensitivity test (SPARCS) over a period of 24 months. METHODS: Our pilot, observational study included 15 patients (30 eyes) with severe POAG. Visual acuity, intraocular pressure, number of anti-glaucoma drugs, visual fields, and SPARCS score were recorded at first visit and at 12 and 24 months. RESULTS: We observed changes in mean deviation (MD) from −19.37 ± 5.04 to −20.63 ± 4.07, mean pattern standard deviation (PSD) from 11.49 ± 2.61 to 11.35 ± 2.01, and mean SPARCS score from 54.97 ± 15.66 to 53.50 ± 16.42. We found no statistically significant difference between visual field parameters and SPARCS scores associated with the number or type of prescribed anti-glaucoma drugs. Spearman’s correlation coefficient of SPARCS at baseline (SPARCS1) versus MD at baseline (MD1) was 0.274 (p = 0.142) and SPARCS1 versus PSD at baseline (PSD1) was −0.163 (p = 0.389). The correlation coefficient between SPARCS at 12 months (SPARCS2) versus MD (MD2) at the same time point was computed to be 0.391 (p = 0.03), whereas SPARCS2 versus PSD at 12 months was −0.212 (p = 0.262). Similarly, we found the coefficient to be 0.336 (p = 0.069) for SPARCS3 (SPARCS at 24 months) versus MD3 (MD at 24 months) and −0.242 (p = 0.197) for SPARCS3 versus PSD3 (PSD at 24 months). Correlation coefficients between SPARCS1/2, SPARCS1/3, MD1/2, MD1/3 PSD1/2, and PSD1/3 were 0.856, 0.865, 0.748, 0.722, 0.497, and 0.562, respectively (p < 0.001). MD changed by 9.46% ± 12.73%, PSD by 0.64% ± 14.03%, and average SPARCS by 3.31% ± 12.73% over 24 months. CONCLUSION: The data from our study indicate the utilitarian application of SPARCS, an inexpensive and readily available tool for monitoring functional deterioration in cases with advanced glaucomatous damage, especially in resource-poor settings. Furthermore, it is a useful and reliable alternative to the imaging modalities where retinal nerve fiber layer measurement can be erroneous in advanced cases secondary to the floor effect. |
format | Online Article Text |
id | pubmed-7780179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-77801792021-01-13 Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test Ichhpujani, Parul Singh, Tanu Thakur, Sahil Singh, Rohan Bir Kumar, Suresh Ther Adv Ophthalmol Original Research PURPOSE: To assess changes in the central and peripheral contrast sensitivity in severe primary open-angle glaucoma (POAG) patients using a computer-based Spaeth/Richman contrast sensitivity test (SPARCS) over a period of 24 months. METHODS: Our pilot, observational study included 15 patients (30 eyes) with severe POAG. Visual acuity, intraocular pressure, number of anti-glaucoma drugs, visual fields, and SPARCS score were recorded at first visit and at 12 and 24 months. RESULTS: We observed changes in mean deviation (MD) from −19.37 ± 5.04 to −20.63 ± 4.07, mean pattern standard deviation (PSD) from 11.49 ± 2.61 to 11.35 ± 2.01, and mean SPARCS score from 54.97 ± 15.66 to 53.50 ± 16.42. We found no statistically significant difference between visual field parameters and SPARCS scores associated with the number or type of prescribed anti-glaucoma drugs. Spearman’s correlation coefficient of SPARCS at baseline (SPARCS1) versus MD at baseline (MD1) was 0.274 (p = 0.142) and SPARCS1 versus PSD at baseline (PSD1) was −0.163 (p = 0.389). The correlation coefficient between SPARCS at 12 months (SPARCS2) versus MD (MD2) at the same time point was computed to be 0.391 (p = 0.03), whereas SPARCS2 versus PSD at 12 months was −0.212 (p = 0.262). Similarly, we found the coefficient to be 0.336 (p = 0.069) for SPARCS3 (SPARCS at 24 months) versus MD3 (MD at 24 months) and −0.242 (p = 0.197) for SPARCS3 versus PSD3 (PSD at 24 months). Correlation coefficients between SPARCS1/2, SPARCS1/3, MD1/2, MD1/3 PSD1/2, and PSD1/3 were 0.856, 0.865, 0.748, 0.722, 0.497, and 0.562, respectively (p < 0.001). MD changed by 9.46% ± 12.73%, PSD by 0.64% ± 14.03%, and average SPARCS by 3.31% ± 12.73% over 24 months. CONCLUSION: The data from our study indicate the utilitarian application of SPARCS, an inexpensive and readily available tool for monitoring functional deterioration in cases with advanced glaucomatous damage, especially in resource-poor settings. Furthermore, it is a useful and reliable alternative to the imaging modalities where retinal nerve fiber layer measurement can be erroneous in advanced cases secondary to the floor effect. SAGE Publications 2020-12-28 /pmc/articles/PMC7780179/ /pubmed/33447729 http://dx.doi.org/10.1177/2515841420977412 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Research Ichhpujani, Parul Singh, Tanu Thakur, Sahil Singh, Rohan Bir Kumar, Suresh Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test |
title | Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test |
title_full | Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test |
title_fullStr | Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test |
title_full_unstemmed | Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test |
title_short | Assessing glaucoma deterioration using Spaeth/Richman contrast sensitivity test |
title_sort | assessing glaucoma deterioration using spaeth/richman contrast sensitivity test |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780179/ https://www.ncbi.nlm.nih.gov/pubmed/33447729 http://dx.doi.org/10.1177/2515841420977412 |
work_keys_str_mv | AT ichhpujaniparul assessingglaucomadeteriorationusingspaethrichmancontrastsensitivitytest AT singhtanu assessingglaucomadeteriorationusingspaethrichmancontrastsensitivitytest AT thakursahil assessingglaucomadeteriorationusingspaethrichmancontrastsensitivitytest AT singhrohanbir assessingglaucomadeteriorationusingspaethrichmancontrastsensitivitytest AT kumarsuresh assessingglaucomadeteriorationusingspaethrichmancontrastsensitivitytest |